ライフサイエンスコーパス: ganciclovir

1 CMV-seropositive donors (147 maribavir; 156 ganciclovir).

2 adiotracers ((18)F-FHBG) or antiviral drugs (ganciclovir).

3 137 for oral ganciclovir and day +135 for IV ganciclovir).

4 hylaxis and received preemptive therapy with ganciclovir.

5 iated with different levels of resistance to ganciclovir.

6 transplantation followed by 28 days without ganciclovir.

7 is not inferior to intravenous therapy with ganciclovir.

8 ced cells through treatment with the prodrug ganciclovir.

9 ectively sensitized EBV(+) lymphoma cells to ganciclovir.

10 MV), including some CMV strains resistant to ganciclovir.

11 fewer hematological adverse events than oral ganciclovir.

12 2.0 mg/0.04 ml of twice weekly intravitreal ganciclovir.

13 rly dividing progenitors by exposing them to ganciclovir.

14 achieved with administration of intravenous ganciclovir.

15 ganciclovir oral solution and of intravenous ganciclovir.

16 ion, all of whom responded to treatment with ganciclovir.

17 discontinuation of tacrolimus and high-dose ganciclovir.

18 prophylaxis with 12 versus 24 weeks of oral ganciclovir.

19 om culture isolates, to detect resistance to ganciclovir.

20 nts received early prophylactic therapy with ganciclovir.

21 and independent of prophylactic exposure to ganciclovir.

22 ovir, and in 1 of 6 patients treated with iv ganciclovir.

23 ctively, and TAF was also twice as potent as ganciclovir.

24 sr39tk) with improved enzymatic activity for ganciclovir.

25 cluding those resistant to the anti-CMV drug ganciclovir.

26 old increase in the EC50) and susceptible to ganciclovir.

27 n can be eliminated by the administration of ganciclovir.

28 l valganciclovir 900 mg twice daily, topical ganciclovir 0.15% 5 applications per day, for 6 weeks) w

29 Patients then either received oral ganciclovir (1 g every 8 hr) or continued IV ganciclovir

30 experiment, a cohort of MCMV+ mice received ganciclovir (10 mg/kg/day subcutaneously) following ceca

31 the most common first-line agents used were ganciclovir (100% and 96.2%) and valganciclovir (23.1%)

32 ntion of CMV disease were compared with oral ganciclovir (1000 mg three times daily) in 303 CMV-seron

33 Of the 500 patients (295 ganciclovir, 205 valganciclovir), 22 patients (4.4%) dev

34 ganciclovir (450 mg/day) was as effective as ganciclovir (3 g/day) for prophylaxis of CMV disease aft

35 ed the effectiveness of three months of oral ganciclovir (3 g/day) versus low-dose valganciclovir (45

36 uced resistance to foscarnet, acyclovir, and ganciclovir (3-, 14-, and 3-fold increases in the 50% ef

37 roup (R-/D+) than patients who received oral ganciclovir (33.3%, P=0.10).

38 ndomized (1:1) to receive either intravenous ganciclovir (5 mg/kg twice daily for 5 days), followed b

39 re treated with intraperitoneal injection of ganciclovir (50 mg/kg) did not develop teratomas when co

40 ganciclovir (1 g every 8 hr) or continued IV ganciclovir (6 mg/kg once per day on Monday-Friday of ea

41 All were treated with high-dose intravenous ganciclovir (7.5-10 mg/kg/12 hr) or oral valganciclovir

42 pted an intensive strategy that consisted of ganciclovir administered before transplantation (5 mg/kg

43 Intravenous ganciclovir administered for 6 weeks improves hearing ou

44 Ablation of the GFP+ cells with chronic ganciclovir administration significantly arrested tumour

45 complete tumor ablation with intraperitoneal ganciclovir administration.

46 enografts were treated with adenoviruses and ganciclovir, all animals showed decreased tumor burden a

47 methyl ethers gave the acyclic acyclovir and ganciclovir analogues.

48 Other than ganciclovir and alpha interferon (IFN-alpha) prophylaxis

49 that hypoxia increased the cell toxicity of ganciclovir and azidothymidine in PEL cells but had no s

50 (thymidine kinase), which can phosphorylate ganciclovir and azidothymidine, respectively.

51 ate and quantify the phosphorylated forms of ganciclovir and azidothymidine, we found that PEL cells

52 plication that had occurred was inhibited by ganciclovir and by neutralizing antibodies against gB.

53 Mutations conferring ganciclovir and cidofovir resistance were detected in CM

54 and I726T conferred a borderline decrease in ganciclovir and cidofovir susceptibility, while Q578L an

55 delivery system was initially reported using ganciclovir and cyclic cidofovir as the prototype compou

56 tion (median time of onset day +137 for oral ganciclovir and day +135 for IV ganciclovir).

57 (if possible): ganciclovir dose escalation, ganciclovir and foscarnet combination, and adjunct thera

58 tion in which viral mutations that conferred ganciclovir and foscarnet resistance had evolved sequent

59 Q578L and G841S conferred slightly decreased ganciclovir and foscarnet susceptibility.

60 litis are oral corticosteroids, intravitreal ganciclovir and laser photocoagulation or vitrectomy.

61 rable efficacy of treatment with intravenous ganciclovir and oral valganciclovir for cytomegalovirus

62 Ganciclovir and PFA also prevented most valproate-induce

63 The anti-viral agents ganciclovir and phosphonoformic acid (PFA) blocked valpr

64 were no significant differences between the ganciclovir and placebo groups in duration of mechanical

65 such as the anti-herpes drugs Aciclovir and Ganciclovir and the anti-cancer drug Clofarabine are now

66 Ganciclovir and valganciclovir are highly effective anti

67 First, the deployment of ganciclovir and valganciclovir for both the prevention a

68 UL97 mutations confer resistance to ganciclovir and valganciclovir, and a UL54 mutation conf

69 rotein of which, respectively, phosphorylate ganciclovir and zidovudine to toxic moieties.

70 Intravenous ganciclovir and, increasingly, oral valganciclovir are n

71 nd was treated alternatively with acyclovir, ganciclovir, and foscavir.

72 treated with a ganciclovir implant plus oral ganciclovir, and in 1 of 6 patients treated with iv ganc

73 n of individual antiviral agents (acyclovir, ganciclovir, and valganciclovir) with outcomes in high-r

74 Acyclovir and ganciclovir are both effective for universal prophylaxis

75 phoma cells in vitro to apoptosis induced by ganciclovir, arginine butyrate in combination with ganci

76 udy does not support routine clinical use of ganciclovir as a prophylactic agent in patients with sep

77 ractices were consistent and mainly involved ganciclovir as first-line agent and foscarnet as second-

78 patients from 1996 to 2000 who received oral ganciclovir as preemptive therapy.

79 EA-D during coexpression or to phosphorylate ganciclovir, as measured by an in-cell activity assay.

80 al load, acute graft-versus-host disease, or ganciclovir-associated neutropenia.

81 rmore, treatment of these chimeric mice with ganciclovir at the time of inoculation led to prolonged

82 ing prophylaxis was also reduced with higher ganciclovir AUC (median predicted incidence, 20% and 10%

83 tion in pediatric LT recipients managed with ganciclovir-based preemptive therapy (PET).

84 Ganciclovir blocks MCMV reactivation, thus preventing ab

85 entiviral vector genomes upon treatment with ganciclovir, but not with vehicle control.

86 ve to treatment with the nucleoside analogue ganciclovir by using a bicistronic construct coexpressin

87 AdV-TK followed by ganciclovir can be administered safely to children with

88 lex virus thymidine kinase (HSV-TK) cDNA and ganciclovir can elicit cytotoxicity to transgene-express

89 l solution provides plasma concentrations of ganciclovir comparable to those achieved with administra

90 were approximately 50-fold less sensitive to ganciclovir compared with cultures of 100% HSV-TK-expres

91 ment of these mice with the antiviral agent, ganciclovir, conditionally ablates proliferating reactiv

92 were completely eliminated after exposure to ganciclovir, confirming function of the suicide trap.

93 Through puromycin selection and ganciclovir counter-selection, a targeting efficiency of

94 with ganR-CMV had received <6 weeks of prior ganciclovir (current guideline-recommended resistance te

95 eral cytomegalovirus retinitis with systemic ganciclovir decreases the risk of development of seconda

96 The greater systemic exposure to ganciclovir delivered by valganciclovir was associated w

97 Each injection was followed by ganciclovir delivered intravenously every 12 hours for 7

98 because of repeated courses of therapy with ganciclovir derivatives.

99 th critical illness due to sepsis or trauma, ganciclovir did not reduce IL-6 levels and the current s

100 e the incidence of CMV infection and, unlike ganciclovir, does not cause myelosuppression.

101 er reducing immunosuppression (if possible): ganciclovir dose escalation, ganciclovir and foscarnet c

102 correlations between individual exposure to ganciclovir during prophylaxis, with CMV viremia inciden

103 potentials of BVP22 and HVP22 to enhance Etk/ganciclovir (Etk/GCV) suicide gene therapy for neuroblas

104 established (12% with maribavir vs. 8% with ganciclovir: event rate difference of 0.041; 95% CI: -0.

105 eased neutropenia and leukopenia with higher ganciclovir exposure.

106 nsplant CMV prophylaxis regimen consisted of ganciclovir followed by 1 year of valganciclovir.

107 bulin [CMVIG] plus four weeks of intravenous ganciclovir followed by two months of valganciclovir); w

108 ceived a minimum of 14 days of postoperative ganciclovir, followed by monthly CMV PCR monitoring.

109 onducted to evaluate the pharmacokinetics of ganciclovir following oral administration of ganciclovir

110 ived prophylaxis with valganciclovir or oral ganciclovir for 100 days.

111 tomegalovirus (CMV) disease with intravenous ganciclovir for 6 weeks has been shown to improve audiol

112 th standard prophylaxis (n = 45, intravenous ganciclovir for four weeks).

113 noninferiority of maribavir compared to oral ganciclovir for prevention of CMV disease was not establ

114 Experience with high-dose ganciclovir for the management of resistant cytomegalovi

115 rospectively in 2 clinical trials evaluating ganciclovir for the treatment of symptomatic congenital

116 omparing oral valganciclovir and intravenous ganciclovir for treatment of cytomegalovirus disease in

117 perior to that of existing antiherpes drugs, ganciclovir (for HCMV) and acyclovir (for HSV-1 and VZV)

118 he half maximal effective concentrations for ganciclovir, foscarnet, and cidofovir were 8.6-, 3.4- an

119 resistant (RR) to available antivirals ([val]ganciclovir, foscarnet, cidofovir) are associated with h

120 Mean daily areas under the curve (AUCs) of ganciclovir from valganciclovir and oral ganciclovir wer

121 that in 23 patients treated with intravenous ganciclovir (GCV) (T(1/2) = 1.73 days; P=.63).

122 Ganciclovir (GCV) and acyclovir (ACV) are guanine nucleo

123 y used as a suicide gene in combination with ganciclovir (GCV) and as a nuclear imaging reporter gene

124 13A, found in a clinical specimen, conferred ganciclovir (GCV) and cidofovir resistance but not fosca

125 reatment for 14 days with the antiviral drug ganciclovir (GCV) depleted Dcx-expressing and BrdU-label

126 we show that the FDA-approved antiviral drug ganciclovir (GCV) induces a type I interferon response i

127 covered unexpectedly that the antiviral drug ganciclovir (GCV) inhibits the proliferation of microgli

128 Prophylactic ganciclovir (GCV) is used in high-risk renal transplant

129 Administration of ganciclovir (GCV) kills actively dividing cells expressi

130 emoprophylaxis with valganciclovir (VGCV) or ganciclovir (GCV) on CMV replication and morbidity.

131 into hepatoma cell lines in the presence of ganciclovir (GCV) pro-drug.

132 gene product in combination with the prodrug ganciclovir (GCV) produces a potent toxin, which affects

133 r survival in renal transplant patients, and ganciclovir (GCV) prophylaxis is associated with improve

134 ate SCI and treated with the antiviral agent ganciclovir (GCV) to ablate dividing, reactive, transgen

135 using transgenic p16-3MR mice, which permit ganciclovir (GCV) to selectively kill senescent cells ex

136 -type mice, were specifically depleted after ganciclovir (GCV) treatment for 14 days.

137 tion of prodrugs 5-fluorocytosine (5-FC) and ganciclovir (GCV) was less efficacious than sequential t

138 blation phase induced by the HSVtk pro-drug, ganciclovir (GCV), oocyte numbers declined due to a disr

139 Interestingly, ganciclovir (GCV), the first line of therapy for human c

140 H) to evaluate the efficacy of HDACI and the ganciclovir (GCV)-mediated anticancer effect contributed

141 g HSCs susceptible to killing in response to ganciclovir (GCV).

142 can be ablated in an inducible manner using ganciclovir (GCV).

143 apeutic gene in conjunction with the prodrug ganciclovir (GCV).

144 equent altered susceptibility to the prodrug ganciclovir (GCV).

145 ex virus thymidine kinase type 1 (HSVtk) and ganciclovir (GCV).

146 ion in plasma was significantly lower in the ganciclovir group (12% [10 of 84 patients] vs 39% [28 of

147 and 28.6% (6/21) of the patients in the oral ganciclovir group (P>0.20).

148 was -0.79 log10 units (-2.06 to 0.48) in the ganciclovir group and -0.79 log10 units (-2.14 to 0.56)

149 The ganciclovir group had more median VFDs in both the inten

150 for the valganciclovir group versus the oral ganciclovir group or patients without CMV infection (P>0

151 o group, P = .76), or mortality (12% for the ganciclovir group vs 15% for the placebo group, P = .54)

152 econdary bacteremia or fungemia (15% for the ganciclovir group vs 15% for the placebo group, P = .67)

153 ified sepsis subgroup (ITT group: 23 days in ganciclovir group vs 20 days in the placebo group, P = .

154 up, P = .05; sepsis subgroup, 23 days in the ganciclovir group vs 20 days in the placebo group, P = .

155 on of mechanical ventilation (5 days for the ganciclovir group vs 6 days for the placebo group, P = .

156 P = .67), ICU length of stay (8 days for the ganciclovir group vs 8 days for the placebo group, P = .

157 reported in which hexadecyloxypropyl-phospho-ganciclovir (HDP-P-GCV) was used as a prototype.

158 resistance, compared with treatment with the ganciclovir implant alone (P=.023; Fisher's exact test).

159 fected eyes) with CMV retinitis treated with ganciclovir implant in the Division of Ocular Immunology

160 placebo, in 5 of 23 patients treated with a ganciclovir implant plus oral ganciclovir, and in 1 of 6

161 eral eyes of 0 of 28 patients treated with a ganciclovir implant plus oral placebo, in 5 of 23 patien

162 nal detachment, were relatively common after ganciclovir implantation but severe vision loss after su

163 mes and the effect of intraocular therapies (ganciclovir implants, intravitreal injections) on ocular

164 One hundred sixty-six eyes received 257 ganciclovir implants.

165 in 12 patients and appropriate initiation of ganciclovir in 4 patients.

166 stem/progenitors at the time of injury with ganciclovir in a nestin-HSV-TK transgenic model, we elim

167 plant recipients receiving valganciclovir or ganciclovir in an international multicenter trial of CMV

168 evious studies, we also eliminated glia with ganciclovir in Gfap(HSV-TK) mice.

169 istered intratumorally or intravenously with ganciclovir in mice lacking a functional adaptive immune

170 inine butyrate and the antiherpes viral drug ganciclovir in the treatment of EBV lymphomas prompted u

171 rmacokinetic study of the use of intravenous ganciclovir in this population, a target AUC12 (area und

172 ptosis either during cell scratch healing or ganciclovir-induced apoptosis.

173 vitro and observational studies suggest that ganciclovir inhibits HHV-8 replication, but no randomize

174 ed, but encouraging, for example in cases of ganciclovir intolerance.

175 s, such as CMV-IgG-negative serostatus; (vi) ganciclovir intolerance; (vii) patients with hypogammagl

176 months of treatment of OD with intravitreal ganciclovir, intravitreal dexamethasone and systemic pre

177 w-volume, intermediate-dose (1.0 mg/0.02 ml) ganciclovir is an efficacious option in developing count

178 Furthermore, as the nucleoside analog ganciclovir is the current drug of choice for treating H

179 typically oral valganciclovir or intravenous ganciclovir) is now almost universal, at least in high-r

180 protein 70 (CMV-hsp70), along with systemic ganciclovir, kills normal melanocytes and raises a CD8+

181 associated with increased prior exposure to ganciclovir (median, 153 vs 91 days, P < .001).

182 eakpoint-dependent expression of EGFP-tk and ganciclovir-mediated apoptosis.

183 nd bystander cells synergistically increased ganciclovir-mediated cytotoxicity to both cell populatio

184 port the molecular engineering, imaging, and ganciclovir-mediated destruction of B7H3 CAR T cells inc

185 We found that ganciclovir-mediated microglial ablation on tga20/CD11b-

186 t valganciclovir unexpectedly binds with the ganciclovir moiety mimicking the N-terminal residue of a

187 who had received chemoprophylaxis with (val-)ganciclovir (n = 63), the CMV-free survival rates at 1 y

188 Therapy primarily involves ganciclovir, now rendered more versatile by data suggest

189 nance dose of 1.0 mg/0.02 ml of intravitreal ganciclovir once weekly after standard induction therapy

190 st-CTL infusion) and 9 required therapy with ganciclovir or foscarnet (only 1 post-CTL infusion).

191 Antiviral treatment with ganciclovir or foscarnet was associated with improved ou

192 rculating neutrophils while receiving either ganciclovir or its prodrug valganciclovir.

193 d that all five compounds were additive with ganciclovir or letermovir.

194 for 5 days), followed by either intravenous ganciclovir or oral valganciclovir once daily until hosp

195 on of PELs with valproate in the presence of ganciclovir or PFA can selectively target tumor cells fo

196 old increase over baseline were treated with ganciclovir or valganciclovir (5 mg/kg or 900 mg twice d

197 ganciclovir following oral administration of ganciclovir or valganciclovir for prophylaxis of cytomeg

198 plantation in 263 patients who received oral ganciclovir or valganciclovir prophylaxis.

199 Doses of ganciclovir or valganciclovir were low in 10 (26%) of 39

200 ively; therefore, we used a thymidine kinase/ganciclovir paradigm to ablate both dividing NG2(+) cell

201 Sixteen of the ganciclovir patients (5.4%) and six of the valganciclovi

202 Furthermore, significantly fewer ganciclovir patients had EC-confirmed CMV disease or CMV

203 MV infections were similar for maribavir and ganciclovir patients.

204 onexpressing bystander cells via transfer of ganciclovir phosphates through gap junctions.

205 ed recently that they transfer low levels of ganciclovir phosphates to bystander cells.

206 Prolonged (val)ganciclovir plus CMVIG reduces viral levels, acute rejec

207 Ganciclovir prescribed for cytomegalovirus prophylaxis i

208 The antiviral drug ganciclovir prevents CMV disease in heart transplant pat

209 To assess the outcome of low-dose-ganciclovir prophylaxis (500 mg twice a day for 3 months

210 Both 24 weeks ganciclovir prophylaxis (O.R. 0.15, 95% C.I. 0.03-0.91,

211 to examine the relationship between 24 weeks ganciclovir prophylaxis and the odds of developing CMV i

212 One D+/R- cohort received ganciclovir prophylaxis for 14 days after transplantatio

213 Oral ganciclovir prophylaxis for 24 weeks is associated with

214 rine CMV (MCMV) renal transplantation model, ganciclovir prophylaxis improved innate infiltrates and

215 These results suggest that ganciclovir prophylaxis may have a long-term beneficial

216 Ganciclovir prophylaxis reduces allograft injury and NK

217 To determine whether ganciclovir prophylaxis reduces plasma interleukin 6 (IL

218 th a historical cohort of children receiving ganciclovir prophylaxis, PET did not differ from prophyl

219 All patients received 3 months of ganciclovir prophylaxis.

220 on, early postoperative enteral feeding, and ganciclovir prophylaxis.

221 inhibitor and a viral replication inhibitor, ganciclovir, represents a possible strategy to eliminate

222 loping CMV disease, there was no evidence of ganciclovir resistance and no mortality over a mean foll

223 e are used to assess the level of associated ganciclovir resistance and therapeutic options.

224 rs and outcomes attributable specifically to ganciclovir resistance appropriately be determined.

225 patients (22 SOT, 17 HCT), 15 had documented ganciclovir resistance mutations and 11 (28%) of 39 had

226 l number of patients (n=3 per arm) had known ganciclovir resistance mutations detected during viral b

227 ease, and disease severity without increased ganciclovir resistance or toxicity.

228 a rapid PCR- and sequencing-based assay for ganciclovir resistance that can be performed in 1 to 2 w

229 higher in HCT than SOT (P = 0.001), although ganciclovir resistance was more common in SOT (P = 0.003

230 Measured levels of ganciclovir resistance were closely comparable when assa

231 dence of an increased incidence of genotypic ganciclovir resistance when compared with those in the 1

232 , acute rejection, opportunistic infections, ganciclovir resistance, and safety.

233 located upstream of UL97 mutations linked to ganciclovir resistance, closer to kinase domains that ar

234 ath, other infections, resource utilization, ganciclovir resistance, quality of life, immune reconsti

235 d substitutions K599E and T601M conferred no ganciclovir resistance, while A591V conferred 3.8-fold-d

236 e codons conferred at least 8-fold-increased ganciclovir resistance, while the level of resistance co

237 th mutations associated with a high level of ganciclovir resistance.

238 served that were of unknown significance for ganciclovir resistance.

239 igh-grade maribavir resistance and low-grade ganciclovir resistance.

240 unistic infections, adverse events, CMV UL97 ganciclovir-resistance mutations, and laboratory abnorma

241 Ganciclovir-resistant (ganR) cytomegalovirus (CMV) is an

242 tion or recurrent disease, and patients with ganciclovir-resistant CMV infection or who are intoleran

243 g and 1 heart transplants) with recurrent or ganciclovir-resistant CMV infection were recruited, and

244 Ganciclovir-resistant cytomegalovirus can cause disease

245 pediatric thoracic transplant patients with ganciclovir-resistant infection, or in serious or compli

246 Outcomes of existing treatment for ganciclovir-resistant or refractory CMV are suboptimal,

247 ose who had received foscarnet treatment for ganciclovir-resistant or refractory CMV infection.

248 High doses of ganciclovir resolved the viremia, which could subsequent

249 Only through direct comparison of ganR- and ganciclovir-sensitive (ganS) CMV infection can risk fact

250 sing cells, addition of hydroxyurea restored ganciclovir sensitivity.

251 Both acyclovir and ganciclovir statistically significantly prevented CMV or

252 The ganciclovir susceptibilities of 17 mutants in this codon

253 y uncharacterized genotypic changes affected ganciclovir susceptibility, especially in those receivin

254 individually confer 5- to 10-fold-decreased ganciclovir susceptibility, except that a 3-fold decreas

255 ion demonstrating a significant reduction in ganciclovir susceptibility.

256 phenotypic assay of the resulting virus for ganciclovir susceptibility.

257 V resistance without significantly affecting ganciclovir susceptibility.

258 substitutions were newly confirmed to alter ganciclovir susceptibility: A505V and I726T conferred a

259 ioretinitis, received localized and systemic ganciclovir, systemic cidofovir analog, and localized fo

260 Six of the 12 patients were started on ganciclovir therapy within 6.8 h; 4 of these were treate

261 poptosis were examined at 0, 4 and 8 days of ganciclovir/thymidine kinase gene therapy.

262 yme/prodrug systems such as thymidine kinase/ganciclovir (TK/GCV), yeast cytosine deaminase/5-fluoroc

263 We prospectively administered 24 weeks ganciclovir to 31 D+/R- recipients.

264 In contrast, administration of ganciclovir to Gfap(HSV-TK) mice eliminated fewer glia b

265 These mice were then treated with ganciclovir to specifically target only the vGPCR-expres

266 dine kinase can phosphorylate zidovudine and ganciclovir to toxic moieties, and direct activation of

267 It can also phosphorylate zidovudine and ganciclovir to toxic moieties, enabling treatment of KSH

268 lants (8.3+/-0.9; P<0.01), which improved in ganciclovir-treated allografts (9.5+/-1.4).

269 cted grafts (P<0.05), which decreased in the ganciclovir-treated grafts.

270 Furthermore, ganciclovir-treated mice did not demonstrate abnormal pu

271 of viraemia (p=0.0480) and number of days of ganciclovir treatment (p=0.0287) were reduced in vaccine

272 Ganciclovir treatment following cecal ligation and punct

273 arrested tumour growth, and combined TMZ and ganciclovir treatment impeded tumour development.

274 beta-cells express a viral thymidine kinase, ganciclovir treatment induced hyperglycemia, providing a

275 Finally, ganciclovir treatment prevented pulmonary fibrosis follo

276 Rapamycin delayed CMV reactivation and ganciclovir treatment was effective at high doses.

277 n situ and tumor killing by thymidine kinase/ganciclovir treatment, but neither strategy alone, provo

278 cells were purged from surviving mice after ganciclovir treatment.

279 Eight patients received ganciclovir treatment.

280 irus, as well as increased susceptibility to ganciclovir treatment.

281 P pool, which should lessen competition with ganciclovir triphosphate for DNA incorporation.

282 d dGTP pools without significantly affecting ganciclovir triphosphate levels.

283 ough hydroxyurea significantly increased the ganciclovir triphosphate:dGTP value for 12 to 24 hours i

284 a suggest that the prolonged increase in the ganciclovir triphosphate:dGTP value in cells in cocultur

285 3000 cytomegalovirus genomes per mL received ganciclovir until two consecutive undetectable cytomegal

286 on (hazard ratio=0.22, P=0.03) compared with ganciclovir usage.

287 the 3 months prior to the IFI, C. glabrata, ganciclovir use in the 3 months prior to the IFI, diabet

288 ugs are used for preventing or treating CMV: ganciclovir, valganciclovir, foscarnet, and cidofovir.

289 High-dose ganciclovir/valganciclovir can be an option in the treat

290 onsisted in all patients of antiviral drugs (ganciclovir/valganciclovir) combined with anti-CMV Ig fo

291 ppressed during prophylaxis when exposure to ganciclovir was 40-50 microg.h/ml, AUCs typical of those

292 after initiation of valganciclovir and oral ganciclovir was 80.5% versus 50.7% at 1 week, 99.5% vers

293 lovir, arginine butyrate in combination with ganciclovir was administered in 15 patients with refract

294 Ganciclovir was administered twice daily at standard dos

295 CMV resistance to foscarnet and ganciclovir was detected after only 6 and 11 weeks of th

296 TD for arginine butyrate in combination with ganciclovir was established as 1000 mg/(kg/day).

297 The combination of arginine butyrate and ganciclovir was reasonably well-tolerated and appears to

298 Ganciclovir was the main treatment in both groups.

299 of ganciclovir from valganciclovir and oral ganciclovir were 46.3 +/- 15.2 and 28.0 +/- 10.9 microg.

300 who received antiviral prophylaxis with oral ganciclovir were retrospectively analyzed using Cox prop

301 end-organ disease can be prevented by giving ganciclovir when viraemia is detected in allograft recip